Loading...
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James, N Sydes, M Mason, M Clarke, Noel W Anderson, J Dearnaley, D Dwyer, J Jovic, G Ritchie, A Russell, J
James, N
Sydes, M
Mason, M
Clarke, Noel W
Anderson, J
Dearnaley, D
Dwyer, J
Jovic, G
Ritchie, A
Russell, J
Citations
Altmetric:
Abstract
Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting first-line, long-term hormone therapy. Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib (arm D) with hormone therapy alone (control arm A).
Description
Date
2012-05
Publisher
Collections
Keywords
Type
Article
Citation
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. 2012, 13 (5):549-58 Lancet Oncol